Figure 3.

Zfra peptide, Hyal-2 antibody, or WWOX phospho-antibody inhibits basal cell carcinoma (BCC) growth in nude mice. Nude mice were pretreated with Zfra4-10 peptide (3 mM in 100 μL H2O) or sterile Milli-Q H2O via tail vein injections for three consecutive weeks, followed by injecting with an indicated antibody or normal rabbit serum (10 μL; diluted with 90 μL PBS). A week later, mice were subcutaneously inoculated with skin cancer BCC cells (two million cells on flank). A representative data is shown from two experiments. (A,C,E) In the control groups, sterile Milli-Q water (100 μL) and normal rabbit serum (10 μL in 100 μL H2O) did not block BCC growth (A). Water with Hyal-2 antiserum strongly suppressed BCC growth (C), whereas water with pY33-WWOX was less effective (E). (B,D,F) In the Zfra groups, Zfra4-10 peptide and normal rabbit serum suppressed BCC growth by ~75% (B), and Zfra4-10 peptide plus pY33-WWOX antiserum strongly blocked BCC growth by > 99% (F). There was no synergistic effect between Zfra4-10 peptide and anti-Hyal-2 antibody in achieving a greater suppression (~75% suppression) (D). (G) A bar graph shows an average of two tumor volumes. (H–N) NOD-SCID mice received three injections of an indicated antiserum (or normal serum or Milli-Q water) in a week and were then allowed to rest for one week followed by inoculation with BCC cancer cells. The extent of tumor growth was examined. The bar graph shows an average of two tumors.